Sponsor Check › Person
Related person on Form D filings · address states as listed: CA, NJ, A1, MA, PA, NY, WA · listed Dec 8, 2008 → Jun 11, 2024
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:56 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:56 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:56 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
3 of 52 offerings report sales commissions totalling $5,651,800; 0 report finder's fees; 1 reports proceeds to related persons totalling $900,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Jun 11, 2024 D File 021-515688 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 17, 2023 D File 021-476128 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 29, 2022 D File 021-469166 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 22, 2021 D File 021-396782 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 27, 2021 D File 021-387450 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 28, 2020 D File 021-376482 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 5, 2020 D File 021-372570 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 22, 2020 D File 021-371555 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 2, 2020 D/A File 021-327473 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 2, 2020 D File 021-364188 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 9, 2019 D File 021-350688 | $2,500,000 | $0 | $0 | Bruce Roberts BrokerCheck CRD 2359901 ↗ via Beech Hill Securities, Inc. (CRD 24771 ↗) Byung-Chan (Ted) Moon BrokerCheck CRD 4914744 ↗ via Beech Hill Securities, Inc. (CRD 24771 ↗) Yarone Breski BrokerCheck CRD 5785868 ↗ via Beech Hill Securities, Inc. (CRD 24771 ↗) |
| EDGAR ↗ | Jul 29, 2019 D File 021-345261 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 11, 2019 D/A File 021-294038 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 3, 2018 D File 021-327013 | $2,743,800 (est.) | $0 | $0 | Raymond James & Associates, Inc. BrokerCheck CRD 705 ↗ |
| EDGAR ↗ | Oct 11, 2018 D/A File 021-246718 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Aug 24, 2018 D/A File 021-275911 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 17, 2018 D File 021-319505 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 2, 2017 D File 021-291967 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 31, 2017 D File 021-279697 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 4, 2017 D/A File 021-254438 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 6, 2016 D File 021-254662 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 21, 2015 D/A File 021-235733 | $0 | $0 | $900,000 (est.) | None listed on this filing |
| EDGAR ↗ | Jul 13, 2015 D/A File 021-241558 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 3, 2015 D File 021-233381 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 23, 2014 D File 021-216115 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 20, 2013 D File 021-201639 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 19, 2013 D File 021-199943 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 2, 2013 D/A File 021-185355 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 11, 2013 D File 021-197788 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director, or promoter will receive any payments from the proceeds of this offering. | None listed on this filing |
| EDGAR ↗ | Apr 1, 2013 D File 021-194308 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 3, 2013 D File 021-189330 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 25, 2012 D File 021-184613 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 18, 2012 D/A File 021-40668 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering. | None listed on this filing |
| EDGAR ↗ | Jan 31, 2012 D File 021-172696 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 22, 2011 D File 021-170592 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 16, 2011 D File 021-168810 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 28, 2011 D File 021-167978 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 26, 2011 D File 021-166388 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 1, 2011 D File 021-165275 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 18, 2011 D File 021-164648 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 12, 2011 D File 021-162710 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 17, 2011 D File 021-159929 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 11, 2011 D File 021-155187 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 11, 2011 D File 021-155188 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 28, 2010 D File 021-149731 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 21, 2010 D/A File 021-146206 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 25, 2010 D File 021-144021 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 25, 2010 D File 021-144022 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 16, 2010 D File 021-140721 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 15, 2010 D File 021-140699 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 17, 2009 D File 021-69966 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 8, 2008 D File 021-60286 | $408,000 | $0 | $0 | Seaview Securities LLC BrokerCheck CRD 126180 ↗ |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Bright Peak Therapeutics, Inc. | Director | Jun 11, 2024 | D | $89,999,991 similar: $500,000–$7,000,000 | $89,999,991 | 21 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | PAIGE.AI, Inc. | Director | Mar 17, 2023 | D | $38,999,891 similar: $829,831–$9,999,998 | $19,499,894 | 3 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | SonoThera, Inc. | Director | Dec 29, 2022 | D | $60,750,000 similar: $2,000,000–$19,999,994 | $30,375,000 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ViaCyte Inc. | Director | Apr 22, 2021 | D | $58,506,166 similar: $2,000,000–$19,999,994 | $53,931,166 | 22 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | PAIGE.AI, Inc. | Director | Jan 27, 2021 | D | $100,000,000 similar: $829,831–$9,999,998 | $55,000,016 | 3 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | ESCAPE Bio, Inc. | Director | Sep 28, 2020 | D | $73,000,000 similar: $2,000,000–$19,999,994 | $73,000,000 | 29 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ImmPACT Bio USA Inc. | Director | Aug 5, 2020 | D | $5,500,000 similar: $2,000,000–$19,999,994 | $3,750,000 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Magnolia Neurosciences Corp | Director | Jul 22, 2020 | D | $17,909,091 similar: $2,000,000–$19,999,994 | $5,000,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ViaCyte Inc. | Director | Apr 2, 2020 | D | $36,018,634 similar: $2,000,000–$19,999,994 | $32,645,780 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Rodeo Therapeutics Corp | Director | Apr 2, 2020 | D/A | $8,950,000 similar: $2,000,000–$19,999,994 | $8,950,000 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Adicet Bio, Inc. | Director | Oct 9, 2019 | D | $80,000,000 similar: $2,000,000–$19,999,994 | $80,000,000 | 18 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ESCAPE Bio, Inc. | Director | Jul 29, 2019 | D | $35,000,000 similar: $2,000,000–$19,999,994 | $31,073,380 | 22 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Proniras Corp | Director | Jul 11, 2019 | D/A | $4,300,000 similar: $2,000,000–$19,999,994 | $4,300,000 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Rodeo Therapeutics Corp | Director | Mar 29, 2019 | D/A | $7,949,999 similar: $2,000,000–$19,999,994 | $7,949,999 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Rodeo Therapeutics Corp | Director | Dec 10, 2018 | D | $4,571,475 similar: $2,000,000–$19,999,994 | $3,685,714 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ViaCyte Inc. | Director | Dec 3, 2018 | D | $90,021,103 similar: $2,000,000–$19,999,994 | $35,833,603 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ESCAPE Bio, Inc. | Director | Oct 11, 2018 | D/A | $63,002,700 similar: $2,000,000–$19,999,994 | $63,002,700 | 31 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ApoGen Biotechnologies, Inc. | Director | Aug 24, 2018 | D/A | $7,565,892 similar: $2,000,000–$19,999,994 | $7,565,892 | 24 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Magnolia Neurosciences Corp | Director | Aug 17, 2018 | D | $13,090,909 similar: $2,000,000–$19,999,994 | $8,000,000 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Proniras Corp | Director | Sep 5, 2017 | D | $2,800,000 similar: $2,000,000–$19,999,994 | $2,800,000 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Rodeo Therapeutics Corp | Director | Aug 2, 2017 | D | $5,900,000 similar: $2,000,000–$19,999,994 | $5,354,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ESCAPE Bio, Inc. | Director | Jun 2, 2017 | D/A | $63,000,000 similar: $829,831–$9,999,998 | $46,002,700 | 32 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | PhaseBio Pharmaceuticals Inc | Director | Jan 31, 2017 | D | $7,875,000 similar: $2,000,000–$19,999,994 | $6,615,000 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Lodo Therapeutics Corp | Director | Jan 4, 2017 | D/A | $19,867,600 similar: $2,000,000–$19,999,994 | $19,867,600 | 13 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ApoGen Biotechnologies, Inc. | Director | Dec 8, 2016 | D | $7,315,892 similar: $2,000,000–$19,999,994 | $3,815,892 | 23 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Petra Pharma Corp | Director | Jan 6, 2016 | D | $10,410,478 similar: $2,000,000–$19,999,994 | $9,992,200 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Lodo Therapeutics Corp | Director | Jan 4, 2016 | D | $3,658,304 similar: $2,000,000–$19,999,994 | $3,517,600 | 13 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ESCAPE Bio, Inc. | Director | Aug 31, 2015 | D | $55,002,700 similar: $829,831–$9,999,998 | $20,002,700 | 6 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | PhaseBio Pharmaceuticals Inc | Director | Jul 21, 2015 | D/A | $42,000,000 similar: $2,000,000–$19,999,994 | $21,000,000 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CATALYST BIOSCIENCES INC | Director | Jul 13, 2015 | D/A | $2,000,000 similar: $2,000,000–$19,999,994 | $1,890,938 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CATALYST BIOSCIENCES INC | Director | Jun 11, 2015 | D | $1,000,000 similar: $2,000,000–$19,999,994 | $1,000,000 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | PhaseBio Pharmaceuticals Inc | Director | Mar 12, 2015 | D | $40,000,000 similar: $2,000,000–$19,999,994 | $20,000,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CATALYST BIOSCIENCES INC | Director | Feb 3, 2015 | D | $5,000,000 similar: $2,000,000–$19,999,994 | $3,224,993 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CATALYST BIOSCIENCES INC | Director | Apr 23, 2014 | D | $5,009,841 similar: $2,000,000–$19,999,994 | $5,009,841 | 18 similar: 2–16 | $3,000 similar: $10,000–$50,000 |
| EDGAR ↗ | CATALYST BIOSCIENCES INC | Director | Aug 20, 2013 | D | $800,008 similar: $2,000,000–$19,999,994 | $400,004 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ViaCyte Inc. | Director | Jul 19, 2013 | D | $27,175,642 similar: $2,000,000–$19,999,994 | $12,150,824 | 55 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | GENOCEA BIOSCIENCES, INC. | Director | Jul 2, 2013 | D/A | $30,500,000 similar: $2,000,000–$19,999,994 | $30,500,000 | 21 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Protagonist Therapeutics, Inc | Director | Jun 11, 2013 | D | $18,040,000 similar: $2,000,000–$19,999,994 | $7,000,000 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AQUINOX PHARMACEUTICALS (USA) INC group: Aquinox Pharmaceuticals | Director | Apr 1, 2013 | D | $20,999,962 similar: $500,000–$7,000,000 | $13,999,975 | 7 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Aldeyra Therapeutics, Inc. | Director | Jan 3, 2013 | D | $8,787,906 similar: $2,000,000–$19,999,994 | $4,793,666 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | GENOCEA BIOSCIENCES, INC. | Director | Oct 11, 2012 | D | $30,500,000 similar: $2,000,000–$19,999,994 | $15,250,000 | 21 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CATALYST BIOSCIENCES INC | Director | Sep 25, 2012 | D | $18,593,361 similar: $2,000,000–$19,999,994 | $13,407,658 | 21 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | PhaseBio Pharmaceuticals Inc | Director | Jun 18, 2012 | D/A | $48,524,067 similar: $2,000,000–$19,999,994 | $48,524,067 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ISCIENCE INTERVENTIONAL CORP | Director | Jan 31, 2012 | D | $5,000,000 similar: $829,831–$9,999,998 | $2,759,185 | 12 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Eiger BioPharmaceuticals, Inc. group: Eiger Biopharmaceuticals | Director | Dec 22, 2011 | D | $500,000 similar: $2,000,000–$19,999,994 | $500,000 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Eiger BioPharmaceuticals, Inc. group: Eiger Biopharmaceuticals | Director | Nov 16, 2011 | D | $500,000 similar: $2,000,000–$19,999,994 | $330,000 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Eiger BioPharmaceuticals, Inc. group: Eiger Biopharmaceuticals | Director | Oct 28, 2011 | D | $200,000 similar: $2,000,000–$19,999,994 | $200,000 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AQUINOX PHARMACEUTICALS (USA) INC group: Aquinox Pharmaceuticals | Director | Sep 26, 2011 | D | $3,536,035 similar: $1,694,259–$16,000,000 | $3,536,035 | 6 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Eiger BioPharmaceuticals, Inc. group: Eiger Biopharmaceuticals | Director | Sep 1, 2011 | D | $250,000 similar: $2,000,000–$19,999,994 | $250,000 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ISCIENCE INTERVENTIONAL CORP | Director | Aug 18, 2011 | D | $3,000,000 similar: $829,831–$9,999,998 | $3,000,000 | 1 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Eiger BioPharmaceuticals, Inc. group: Eiger Biopharmaceuticals | Director | Jul 12, 2011 | D | $400,000 similar: $1,694,259–$16,000,000 | $400,000 | 2 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | ISCIENCE INTERVENTIONAL CORP | Director | May 17, 2011 | D | $6,000,000 similar: $829,831–$9,999,998 | $5,335,545 | 12 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | AQUINOX PHARMACEUTICALS (USA) INC group: Aquinox Pharmaceuticals | Director | Feb 11, 2011 | D | $4,724,298 similar: $1,694,259–$16,000,000 | $4,724,298 | 6 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | AQUINOX PHARMACEUTICALS INC group: Aquinox Pharmaceuticals | Director | Feb 11, 2011 | D | $9 similar: $1,694,259–$16,000,000 | $9 | 6 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | PhaseBio Pharmaceuticals Inc | Director | Dec 6, 2010 | D/A | $25,300,001 similar: $2,000,000–$19,999,994 | $25,300,001 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Eiger BioPharmaceuticals, Inc. group: Eiger Biopharmaceuticals | Director | Oct 28, 2010 | D | $4,000,000 similar: $1,694,259–$16,000,000 | $2,500,000 | 7 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | ISCIENCE INTERVENTIONAL CORP | Director | Sep 21, 2010 | D/A | $10,000,000 similar: $829,831–$9,999,998 | $5,087,965 | 18 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | ISCIENCE INTERVENTIONAL CORP | Director | Aug 11, 2010 | D | $3,601,069 similar: $829,831–$9,999,998 | $3,601,069 | 15 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | AQUINOX PHARMACEUTICALS INC group: Aquinox Pharmaceuticals | Director | Jun 25, 2010 | D | $6 similar: $1,694,259–$16,000,000 | $6 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | AQUINOX PHARMACEUTICALS (USA) INC group: Aquinox Pharmaceuticals | Director | Jun 25, 2010 | D | $3,531,483 similar: $1,694,259–$16,000,000 | $3,531,483 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | AQUINOX PHARMACEUTICALS INC group: Aquinox Pharmaceuticals | Director | Apr 16, 2010 | D | $9 similar: $1,694,259–$16,000,000 | $9 | 5 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | AQUINOX PHARMACEUTICALS (USA) INC group: Aquinox Pharmaceuticals | Director | Apr 15, 2010 | D | $6,227,549 similar: $1,694,259–$16,000,000 | $4,827,549 | 5 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | PhaseBio Pharmaceuticals Inc | Director | Jan 5, 2010 | D | $25,300,001 similar: $2,000,000–$19,999,994 | $10,120,000 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Eiger BioPharmaceuticals, Inc. group: Eiger Biopharmaceuticals | Director | Dec 17, 2009 | D | $6,500,000 similar: $1,694,259–$16,000,000 | $3,500,000 | 6 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Eiger BioPharmaceuticals, Inc. group: Eiger Biopharmaceuticals | Director | Sep 10, 2009 | D/A | $24,631,114 similar: $1,694,259–$16,000,000 | $21,800,002 | 6 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | CATALYST BIOSCIENCES INC | Director | Dec 8, 2008 | D | $40,399,998 similar: $2,000,000–$19,999,994 | $40,399,998 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); Other Health Care / 506(b) (4,189 filings); Biotechnology / 506(b) (3,253 filings); Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
People and management entities the issuers listed as related persons on the same Form D filings as Asish Xavier. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Asish Xavier appears on a new Form D, or when a court case or SEC action is matched to them. See plans →